Trehu Elizabeth 4
4 · Jounce Therapeutics, Inc. · Filed Mar 31, 2021
Insider Transaction Report
Form 4
Trehu Elizabeth
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-03-29$4.02/sh+5,100$20,502→ 98,685 total - Exercise/Conversion
Common Stock
2021-03-30$4.02/sh+100$402→ 93,685 total - Sale
Common Stock
2021-03-30$10.00/sh−100$1,000→ 93,585 total - Sale
Common Stock
2021-03-29$10.09/sh−5,100$51,459→ 93,585 total - Exercise/Conversion
Common Stock
2021-03-31$4.02/sh+8,300$33,366→ 101,885 total - Sale
Common Stock
2021-03-31$10.09/sh−8,300$83,747→ 93,585 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-30−100→ 212,185 totalExercise: $4.02Exp: 2025-11-12→ Common Stock (100 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-31−8,300→ 203,885 totalExercise: $4.02Exp: 2025-11-12→ Common Stock (8,300 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-29−5,100→ 212,285 totalExercise: $4.02Exp: 2025-11-12→ Common Stock (5,100 underlying)
Footnotes (4)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 25, 2020. The Reporting Person exercised no discretion with respect to these transactions.
- [F2]Represents the weighted average share price of an aggregate total of 5,100 shares sold in the price range of $10.00 to $10.30 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Represents the weighted average share price of an aggregate total of 8,300 shares sold in the price range of $10.00 to $10.21 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]25% of the option shares vested and became exercisable on November 3, 2016 and the remainder of the option shares vest and became exercisable in 12 quarterly installments thereafter.